Octagon Capital Advisors’s Viridian Therapeutics VRDN Stock Holding History

Octagon Capital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-450,000	Closed	-$6.07M	–	36
2025 Q1	$6.07M	Sell	450,000 -420,000	-48%	-$7.15M	1.17%	28
2024 Q4	$16.7M	Hold	870,000	–	–	2.74%	14
2024 Q3	$19.8M	Buy	870,000 +250,000	+40%	+$4.09M	3.08%	11
2024 Q2	$8.07M	Hold	620,000	–	–	1.27%	21
2024 Q1	$10.9M	Hold	620,000	–	–	1.3%	23
2023 Q4	$13.5M	Sell	620,000 -447,143	-42%	-$7.06M	2.16%	13
2023 Q3	$16.4M	Buy	1,067,143 +144,143	+16%	+$2.75M	2.52%	14
2023 Q2	$22M	Sell	923,000 -262,000	-22%	-$6.72M	3.06%	8
2023 Q1	$30.1M	Buy	1,185,000 +360,800	+44%	+$11.6M	4.34%	6
2022 Q4	$24.1M	Buy	+824,200	New	+$19M	3.75%	8

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Octagon Capital Advisors's VRDN Position: Q2 2025 in Review

Octagon Capital Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 450,000 shares — an estimated $6.07M sold.

Octagon Capital Advisors first reported a position in VRDN in Q4 2022 and held it in 10 quarters. The position peaked at $30.1M in Q1 2023. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

Octagon Capital Advisors reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
Octagon Capital Advisors sold 450,000 Viridian Therapeutics shares in Q2 2025, an estimated $6.07M.
Octagon Capital Advisors first reported a position in Viridian Therapeutics in Q4 2022 and held it in 10 quarters.
Octagon Capital Advisors's Viridian Therapeutics position peaked at $30.1M in Q1 2023.
170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Octagon Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.